: This hypothesis remains a central pillar of cardiovascular medicine, having inspired over 8,000 follow-up papers from laboratories worldwide. Clinical Leadership and the Cholesterol Trials
His work continues to influence major research institutions, including the University of Michigan Medical School , where the study of cardiovascular disease and lipid metabolism remains a primary focus of the Frankel Cardiovascular Center . Daniel Steinberg, 1922–2015 - PMC - NIH Daniel Steinberg - Michigan
Steinberg was also noted for his reflective approach to science and medicine. In his memoirs and essays, such as he often explored the human side of high-stakes academic pursuits, questioning the motivations behind rigorous scientific inquiry and the personal costs of professional excellence. : This hypothesis remains a central pillar of
Beyond laboratory work, Steinberg was a critical force in proving that lowering cholesterol actually saves lives. He served as the for the Lipid Research Clinics Coronary Primary Prevention Trial , the first major study to demonstrate that drug-induced lipid lowering could reduce heart attacks. In his memoirs and essays, such as he
: His research showed that oxidized LDL is proinflammatory and immunogenic, explaining the inflammatory nature of arterial lesions.
Steinberg’s most significant scientific contribution was the development of the . Over three decades, he and his colleagues published over 100 manuscripts providing evidence that oxidized LDL cholesterol drives the development of atherosclerosis (the buildup of fats and cholesterol in artery walls).